Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05339750
Other study ID # 21-011596
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 15, 2022
Est. completion date September 23, 2022

Study information

Verified date January 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.


Description:

Study participation involves three visits to the study site on Days 1, 3, and 5, and completion of a demographics and allergy history questionnaire. Researchers will review medical history and current medications. On Day 1 a patch will be applied with 10 allergens and a routine skin examination will be conducted and a photograph will be taken of the forearm. On day 3, subjects will return to remove the patch test and have photographs of the area taken. On day 5, the final assessment for allergic contact dermatitis will be performed and photographs of the area taken. Key Information: The most common side effect of skin testing is slightly swollen, red, itchy bumps (wheals). These wheals may be most noticeable during the test. In some, an area of swelling, redness and itching may develop a few hours after the test and remain for a couple of days. Rarely, allergy skin tests can produce a severe, immediate allergic reaction. The patches are worn on the forearm for 48 hours. During this time, bathing and activities that cause heavy sweating should be avoided. Irritated skin at the patch site may indicate an allergy. If a positive test result is documented, a medical professional will provide education and recommend follow up with primary care provider.


Recruitment information / eligibility

Status Completed
Enrollment 233
Est. completion date September 23, 2022
Est. primary completion date September 23, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Adults over the age of 18 - Willing and able to provide informed consent Exclusion Criteria - Under 18 years of age - Has used topical or oral steroids two weeks prior to patch testing - Currently taking immunosuppression agents or is immunocompromised due to medical condition - No sunburn or rash at site of testing - Women who are breastfeeding or pregnant. - Treatment with ultraviolet (UV) light (including tanning) during the two weeks prior to visit. - Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting patch test area from excess moisture due to showering)

Study Design


Intervention

Device:
AI-based smartphone application
AI-based smartphone application to record and interpret the patch test results
Diagnostic Test:
Allergen patch
Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.

Locations

Country Name City State
United States Mayo Clinic Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary AI algorithms predictions of reactions Number of times the AI algorithms matches the human review of photographs of skin patch tests classification of reaction. The accuracy for the classification of regions within the test panel that either were a reaction (reaction grade 1+) or not (grade 0). 6 months
Secondary Fitzpatrick skin type assessment Number of times the AI algorithms matches the human review of photographs of skin patch tests over the entire range of Fitzpatrick skin types. The Fitzpatrick skin typing categorize skin type according to how much melanin is present. 10 months
See also
  Status Clinical Trial Phase
Completed NCT03945760 - Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects Early Phase 1
Not yet recruiting NCT05498467 - The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis Phase 3
Active, not recruiting NCT03680131 - Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis Phase 2
Recruiting NCT05535738 - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Phase 2/Phase 3
Recruiting NCT06191627 - Patient Experience and Quality of Patch Testing on the Legs vs Back N/A
Completed NCT00867607 - Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis Phase 1/Phase 2
Recruiting NCT00445029 - Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation N/A
Completed NCT04365140 - MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Recruiting NCT05991674 - A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
Completed NCT00931242 - Study of Apremilast in Atopic or Contact Dermatitis Phase 2
Completed NCT01798589 - Bioequivalence of Ethylenediamine Dihydrochloride Study Phase 4
Completed NCT01546298 - Immune Reactions in Contact Dermatitis Affected Skin
Recruiting NCT03935971 - The Effects of Dupilumab on Allergic Contact Dermatitis Phase 4
Completed NCT01797562 - Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents N/A
Not yet recruiting NCT05858723 - Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool N/A
Completed NCT02534441 - Epidemiology and Co-Reactivity of Novel Surfactant Allergens N/A
Not yet recruiting NCT01413477 - Nickel Desensitization Using Topical Therapy N/A
Completed NCT00133341 - Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate Phase 2
Completed NCT00132600 - Clinical Evaluation of Bacitracin Phase 2
Completed NCT03902392 - Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis N/A

External Links